Evonile Pharma Q2 FY27 standalone revenue Rs 247.23 cr

What the numbers show

• Net margin was 8.31% of revenue, up 36 bps from 7.94%.
• Other expenses accounted for Rs 6.05 cr of the Rs 14.85 cr rise in total expenses (40%).
• Cost of materials took 41.3% of revenue, against 42.1% a year earlier.

• Revenue from operations (Q2 FY27 standalone): Rs 247.23 cr vs Rs 231.63 cr in Q2 FY26
• Total income (Q2 FY27 standalone): Rs 251.53 cr vs Rs 234.50 cr in Q2 FY26
• Total expenses (Q2 FY27 standalone): Rs 225.42 cr vs Rs 210.57 cr in Q2 FY26
• Cost of materials consumed (Q2 FY27 standalone): Rs 102.05 cr vs Rs 97.54 cr in Q2 FY26
• Purchases of stock-in-trade (Q2 FY27 standalone): Rs 61.27 cr vs Rs 59.82 cr in Q2 FY26
• Changes in inventories of finished goods, work-in-progress and stock-in-trade (Q2 FY27 standalone): Rs (4.53) cr vs Rs (5.26) cr in Q2 FY26
• Employee benefits expense (Q2 FY27 standalone): Rs 30.36 cr vs Rs 28.59 cr in Q2 FY26
• Finance costs (Q2 FY27 standalone): Rs 0.38 cr vs Rs 0.29 cr in Q2 FY26
• Depreciation and amortisation expense (Q2 FY27 standalone): Rs 4.12 cr vs Rs 3.87 cr in Q2 FY26
• Other expenses (Q2 FY27 standalone): Rs 31.77 cr vs Rs 25.72 cr in Q2 FY26
• Profit before tax (Q2 FY27 standalone): Rs 26.11 cr vs Rs 23.93 cr in Q2 FY26
• Profit after tax (Q2 FY27 standalone): Rs 20.54 cr vs Rs 18.40 cr in Q2 FY26
• Earnings per share – Basic and Diluted (Q2 FY27 standalone): Rs 6.42 vs Rs 5.75 in Q2 FY26

According to the standalone statement of financial results for the quarter ended September 30, 2026, Evonile Pharma Limited reported revenue from operations of Rs 247.23 cr, compared with Rs 231.63 cr in the corresponding quarter ended September 30, 2025. Total income, which includes other income, was Rs 251.53 cr against Rs 234.50 cr in the year-ago quarter.

On the cost side, total expenses rose to Rs 225.42 cr from Rs 210.57 cr a year earlier. Within this, cost of materials consumed increased to Rs 102.05 cr from Rs 97.54 cr, and purchases of stock-in-trade were Rs 61.27 cr versus Rs 59.82 cr. Employee benefits expense moved to Rs 30.36 cr from Rs 28.59 cr, while depreciation and amortisation expense was Rs 4.12 cr compared with Rs 3.87 cr. Other expenses rose to Rs 31.77 cr from Rs 25.72 cr. Finance costs were Rs 0.38 cr versus Rs 0.29 cr in the corresponding prior period. Changes in inventories of finished goods, work-in-progress and stock-in-trade stood at Rs (4.53) cr compared with Rs (5.26) cr in the same quarter last year.

Profit before tax for the quarter ended September 30, 2026 was Rs 26.11 cr, up from Rs 23.93 cr in the quarter ended September 30, 2025. Profit after tax came in at Rs 20.54 cr, compared with Rs 18.40 cr in the year-ago quarter. Basic and diluted earnings per share for the quarter were reported at Rs 6.42, versus Rs 5.75 in the corresponding previous quarter, as per the statement of financial results.